ACCESS TO INSIGHT
|CORE FACULTY &
|CLINICAL RESEARCH GRANT||RECIPIENTS||CONTACT US|
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and, hormone replacement therapy.
Long-term commitment to research and education
Novo Nordisk has been committed to supporting haemostasis research, development, and education for over 20 years.
The Novo Nordisk Haemophilia Foundation (www.nnhf.org) was set up in 2005 as a non-profit independent organisation committed to development projects, fellowships, and offers an annual award in the developing world.
The Haemophilia Academy is an independently run training programme sponsored by an educational grant from Novo Nordisk and is led by a distinguished international faculty of haemophilia experts. The Haemophilia Academy offers an annual training programme for young haemophilia treaters.
For more information please contact: email@example.com
The Novo Nordisk Haemostasis Award has been awarded since 2001 in recognition of outstanding preclinical and/or clinical postgraduate research of a significant and original nature leading to a better understanding of the mode of action and/or the therapeutic potential of recombinant Factor VIIa.
Novo Nordisk Access to Insight aims to further the careers of young haemostasis researchers and to draw attention to haemophilia and other bleeding disorders and their challenges.
Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical community, and society.
Novo Nordisk‘s commitment to the worldwide haemophilia community has resulted in an innovative treatment for haemophilia patients with inhibitors. Novo Nordisk is placing a high priority on sustaining its haemophilia portfolio with new, patent-protected molecules.
Through various in vitro and in vivo studies and clinical development over many years, Novo Nordisk has gained long-standing expertise in coagulation and haemostasis. Novo Nordisk seeks new innovations for preventing and treating bleeding in people with haemophilia with and without inhibitors.